Startup Deep Dive : Synapsica — the radiology AI startup that survived its own founders’ fraud case

A Bengaluru radiology-AI startup once laid off 30 of its roughly 100 employees a month after its own CEO and COO were arrested on a co-founder’s fraud complaint. Four years later, the same company says its software has been used in reports for more than a million patients.

Synapsica makes software that reads spine MRIs and X-rays faster than a human radiologist can type, in a country that has fewer than 10,000 radiologists for over 30,000 imaging centres. It survived a boardroom crisis that would have killed most seed-stage startups, kept its founder as CEO, and is still private, still small, and still trying to prove that AI-assisted reporting is a business and not just a demo.

Quick facts

What they do

Synapsica builds software that sits between a radiology scan and the report a doctor eventually reads. Its products take MRI and X-ray images of the spine, and X-rays of the chest, and generate a structured, near-complete first draft of the radiology report, with measurements, annotated images and standardised language already filled in. Radiologists at hospitals, diagnostic chains and teleradiology providers use it to check and sign off rather than write from scratch. The customers are the imaging centres and hospital radiology departments themselves, not patients directly, and the pitch is speed and consistency in a country where the radiologist-to-scan ratio is badly stretched.

The origin

Meenakshi Singh grew up in Mau, a small town in Uttar Pradesh, in a family of doctors, and saw first-hand what a shortage of radiologists does to a diagnosis: reports delayed, or read too fast by an overworked specialist, or read by someone without the right training at all. She studied engineering at Manipal and did an MBA at IIM Ahmedabad before turning that observation into a company. Her co-founder Kuldeep Singh Chauhan, an IIT Kharagpur graduate, brought the technical half of the insight: that spine and chest imaging, which together account for a large share of routine radiology work, followed patterns structured enough for a machine to learn to read them consistently, taking away the repetitive measurements and clicks and leaving the radiologist to focus on judgement calls. Dr Cherian joined as the clinical and operations co-founder. The company that came out of this was built around one specific bet: that reporting on degenerative spine disease, one of the most common and most repetitive things a radiologist does, could be standardised and sped up with AI, in human-readable language a doctor would actually sign off on.

The struggle years

Synapsica’s setback was not a slow product failure. It was sudden, and it came from inside the founding team. In September 2022, an economic offence wing FIR (No. 179/2021) led to the arrest of CEO Meenakshi Singh and COO Dr Cherian, on a complaint from co-founder Gandharv Goyal alleging he had been defrauded of about ₹16 crore (~$1.7 million). Both remained in judicial custody for months; their bail applications were listed and disposed of by the Delhi High Court on 9 January 2023.

A month after the arrests, in October 2022, the company laid off close to 30 of its roughly 100 employees. CTO Kuldeep Singh Chauhan told the press the cuts were a response to “market conditions” and a broader slowdown, and were not connected to the arrests; the company gave affected staff two months of severance and help finding new jobs. Whatever the internal cause, the sequence was as public as a startup crisis gets: a founder dispute serious enough to reach a criminal court, followed within weeks by a near-third of the workforce going out the door.

Synapsica did not shut down. Meenakshi Singh continued to run the company as CEO through the case and remains CEO as of 2026, according to recent company and government profiles, and the product kept shipping: SpindleX, its stress X-ray spine tool, went on to earn FDA 510(k) clearance, and partnerships signed both before and after the crisis, including with GenWorks Health and distribution ties in the US, stayed in place.

The turning point

The clearest before-and-after marker is not a funding round but the crisis itself and what followed it. Before October 2022: roughly 100 employees, a Series A closed a year earlier, and a founding team of four running the company jointly. After: about 70 employees, a CEO and COO who had spent months in judicial custody before resuming their roles, and a company that had to publicly separate “we are cutting cost” from “our founders are in a fraud case” in the same news cycle. By the time outside trackers next captured headcount, Synapsica Healthcare Private Limited showed 44 employees in April 2024, and by August 2026 independent trackers put group headcount at just 19 — a company that shrank sharply even as its own marketing claimed a million-plus patients served. The turning point, in other words, was less a single moment of triumph than a test of whether the founding team and the product could survive a governance failure. On the evidence of 2026 coverage, both did, in reduced form.

The money behind it

• Angel round: undisclosed amount, September 2019, led by angel investor Mohd Kashif Rashid, who later also became a company director (Crunchbase/Tracxn).
• Seed round: undisclosed amount, March 2020, backed by Y Combinator after the company joined YC’s Winter 2020 batch (Y Combinator company page).
• Second seed round: undisclosed amount, December 2020, led by Stellaris Venture Partners (Tracxn).
• Series A: $4.2 million (reported as ₹31.3 crore at the time), announced June 2021, led by IvyCap Ventures and Endiya Partners, with Y Combinator and angel investors participating (Inc42; BioSpectrum India, February 2022). Synapsica said the capital would fund overseas expansion and new AI features for radiologists.
• Total disclosed funding: reported between $4.36 million (CB Insights) and $4.81 million (Tracxn) across four rounds — the two trackers disagree on the exact total, and neither figure has been confirmed directly by the company beyond the Series A amount.
• Other backers named across trackers: 500 Global (formerly Google for Startups-linked accelerator programme), GoAhead Ventures, Astir Ventures, Edison Accelerator (Tracxn, CB Insights, Dealroom).

No Series B has been publicly reported as of September 2026. What each backer is understood to have changed: Y Combinator pushed the company toward a narrower, faster-shipping product focus typical of its cohorts; IvyCap Ventures and Endiya Partners, as the Series A leads, backed the international-expansion thesis explicitly cited in the 2021 funding announcement; Stellaris’ seed cheque came at a point when the company was still proving out its core spine-reporting algorithms.

How it makes money

Synapsica is a business-to-business software seller into radiology, not a consumer health app. Money comes in from hospitals, diagnostic chains and teleradiology groups that license its reporting tools, either as a per-report or subscription arrangement bundled with their imaging workflow; the company does not publish its exact pricing or take rate. Costs sit mainly in software engineering and clinical/annotation talent needed to keep the underlying models accurate across scanner types and patient populations, plus the sales and integration effort of plugging into a hospital’s existing PACS/RIS systems — which is typically the slow, expensive part of selling into Indian healthcare IT.

• Radiolens: the workflow layer (RIS/PACS automation) that most other products plug into — this is the platform customers first buy.
• Spindle: AI-generated first-draft reporting for MRI spine scans, the company’s original flagship product.
• SpindleX: AI reporting for stress X-rays of the spine, FDA 510(k) cleared (company website), aimed at US and international sales.
• Crescent: AI assistant for chest X-rays, extending the company beyond spine into a much larger imaging category.

The part people get wrong is assuming a report-generation tool like this bills like a diagnostic test. It does not: Synapsica is not doing the diagnosis or billing the patient — it is selling efficiency software to the radiologist’s employer, so its revenue scales with software adoption and seat/volume licensing inside imaging centres, not with patient footfall directly.

The numbers

The gap between FY2021 and FY2025 is real: only one full-rupee revenue figure for the group is publicly filed and unlocked, and it belongs to a small operating base — a company that size does not typically publish granular investor updates. Where a database showed only a percentage change rather than an absolute number, that is what is reported here rather than an invented rupee figure.

• FY2021 revenue: ₹2.07 crore (MCA filing).
• FY2025 revenue trend: down 6.5% year-on-year (Tofler).
• FY2025 net profit trend: up 190.6% year-on-year, with net margin near 7.0% (Tofler) — a smaller but apparently better-run business than at its 2022 peak headcount.

Where the money comes from

• Geography: primarily India, with reported presence in the United States, Africa, Bangladesh and Pakistan across more than 600 locations (The Better India, September 2026).
• Reach into smaller towns: partnership with GenWorks Health, announced December 2021, aimed at more than 300 tier-2 and tier-3 Indian towns (BioSpectrum India).
• Distribution outside India: a 2020 distribution tie-up with The Spinal Kinetics in the United States, and a reported GE Healthcare distribution arrangement for Southeast Asia (BioSpectrum India).
• Clinical validation: a research partnership with AIIMS New Delhi, cited from around 2019–2021 (BioSpectrum India).

The surprise is how much of the stated scale — 2,000-plus radiologists, centres and hospitals, and reports touching more than a million patients — sits on top of a company whose independently verifiable filed revenue is still just a few crore rupees and whose reported headcount has fallen from about 100 in 2022 to about 19 by mid-2026. Either the usage numbers are running well ahead of what shows up in disclosed financials, or a meaningful share of that reach comes through partners like GenWorks and GE Healthcare rather than direct billing — the public record does not resolve which.

The risks

• Governance risk, evidenced not hypothetical: the company’s own CEO and COO were criminally charged by a co-founder over an alleged ₹16 crore fraud in 2022 — a documented event, not a theoretical scenario, and the kind of dispute that can resurface with investors or acquirers during any future fundraise or exit.
• Shrinking headcount alongside claimed scale: independent trackers show employee count falling from roughly 100 (2022) to 44 (April 2024) to about 19 (August 2026), even as the company’s own claims of patients served and locations covered have grown — a mismatch that a buyer or investor doing diligence would need explained.
• Thin, largely undisclosed financial base: only one year of filed revenue (FY2021, ₹2.07 crore) is publicly available in absolute terms, with only percentage trend data for FY2025 — this makes it hard for outsiders to verify the company’s own scale claims against its books.
• Regulatory dependence for international sales: SpindleX’s push into markets like the US leans on FDA 510(k) clearance staying valid and further clearances following for other products, a slower and costlier path than selling only in India.

The takeaway

The lesson in Synapsica’s story is not really about AI or radiology. It is about what actually kills — or doesn’t kill — an Indian startup at the seed-to-Series-A stage. Product risk and market risk are the ones founders spend their pitch decks on. Synapsica’s near-death moment came from neither: it came from a fraud complaint between its own co-founders, playing out in an economic offence wing FIR and a Delhi High Court bail docket, with the layoffs that followed almost incidental by comparison. The company kept its CEO, kept shipping products, and got a US regulatory clearance after the crisis, which counts as a genuine recovery. But recovery is not the same as proof of a durable business — a workforce a fifth the size it was in 2022, and financial disclosures that stop at a single filed year, are exactly the gaps a well-read investor would want closed before calling this one solved.

Frequently asked questions

What does Synapsica actually sell?

Software that generates a structured first-draft radiology report — mainly for MRI and X-ray imaging of the spine, and X-rays of the chest — which a radiologist then checks and signs off, sold to hospitals, diagnostic centres and teleradiology providers rather than to patients.

Who founded Synapsica and when?

Meenakshi Singh (CEO), Kuldeep Singh Chauhan (CTO) and Dr Cherian (COO), along with co-founder Gandharv Goyal. Most trackers date the company to 2018; its main operating entity, Synapsica Healthcare Private Limited, was incorporated on 23 December 2019.

How much funding has Synapsica raised?

Its only publicly confirmed round is a $4.2 million Series A in June 2021, led by IvyCap Ventures and Endiya Partners with Y Combinator participating. Trackers estimate total funding across all rounds, including earlier angel and seed money, at between $4.36 million and $4.81 million; no Series B has been publicly reported as of September 2026.

What happened with the fraud case involving its CEO and COO?

In September 2022, CEO Meenakshi Singh and COO Dr Cherian were arrested following an economic offence wing FIR filed on a complaint from co-founder Gandharv Goyal, who alleged he had been defrauded of about ₹16 crore. Both were granted bail, with applications disposed of by the Delhi High Court in January 2023, and Meenakshi Singh has continued as CEO.

Is Synapsica profitable or public?

Synapsica is a private company; it has not listed on any exchange and has no reported IPO plans. Its only publicly filed absolute revenue figure, ₹2.07 crore for FY2021, does not disclose profit or loss; a more recent tracker estimate for FY2025 shows revenue down 6.5% year-on-year but net profit up 190.6% year-on-year, without disclosing the underlying rupee amounts.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42, “Synapsica Healthcare Has Raised $4.2 Mn Funding In Its Series A” — June 2021
• BioSpectrum India, “#startupoftheday 113 – Synapsica” — February 2022
• BioSpectrum India, “Synapsica Healthcare raises $4.2 M for global expansion” — June 2021
• Y Combinator, Synapsica Healthcare company page — accessed September 2026
• The Better India, “Innovation Helps Radiologists Read MRIs in Under a Minute, Has Served 1 Million People” — September 2026
• NITI Aayog Frontier Tech, “Reimagining Radiology: Faster, Smarter Diagnostics With AI” — 2026
• YourStory, “Synapsica lays off 30% staff month after CEO, COO…” — October 2022
• SightsInPlus, “Synapsica CEO, COO arrested for Rs. 16 cr fraud; layoff 30% staff” — October 2022
• Delhi High Court cause lists, Bail Applications 3314/2022 and 3758/2022 (FIR No. 179/2021, EOW) — January 2023
• Tracxn, Synapsica company profile — accessed September 2026
• CB Insights, Synapsica company profile — accessed September 2026
• Dealroom.co, Synapsica Healthcare company profile — accessed September 2026
• thecompanycheck.com, Synapsica Healthcare Private Limited (CIN U74999DL2019PTC359165) — accessed September 2026
• thecompanycheck.com, Synapsica Technologies Private Limited (CIN U74999DL2017PTC320790) — accessed September 2026
• Tofler, Synapsica Technologies Private Limited financial summary — accessed September 2026
• Synapsica, SpindleX product page (FDA 510(k) clearance) — accessed September 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.